Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eVLP RSV vaccine
- Development stage
- Preclinical
- Lead developer
- RNACure Biopharma
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **eVLP RSV vaccine** is an investigational mRNA-based vaccine candidate developed using EABR (ESCRT- and ALIX-binding region) technology to encode self-assembling enveloped virus-like particles (eVLPs) displaying RSV pre-fusion F (Pre-F) protein. It elicits superior neutralizing antibodies targeting Pre-F-specific sites compared to conventional Pre-F or ferritin nanoparticle mRNA vaccines, with enhanced Th1-biased cellular immunity and broader protection against RSV strains including clinical isolates ON1 (RSV-A) and BA9 (RSV-B). In preclinical mouse models, it demonstrated dramatically reduced pulmonary viral loads post-RSV challenge and stronger cross-neutralization than approved subunit vaccines like Pfizer's Abrysvo.[2][4]
- Other names
- Pre-F-EABR mRNA vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on eVLP RSV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eVLP RSV vaccine.